Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2017 Filed May 24, 2017 22:55 UTC |
WHITE SARA JDirector
|
GrantCommon Stock | 2,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007937 · edgar.xml · nonDerivative · entry 2 WHITE SARA J · CIK 0001227559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,133 F1 · shares: Grant of restricted shares in consideration of services as a Board Member. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:54 UTC |
Moore Vance B.Director
|
GrantCommon Stock | 243 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007936 · edgar.xml · nonDerivative · entry 3 Moore Vance B. · CIK 0001550553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,658 F2 · shares: Grant of restricted shares in consideration of services as a member of the Compensation Committee. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:54 UTC |
Moore Vance B.Director
|
GrantCommon Stock | 2,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007936 · edgar.xml · nonDerivative · entry 2 Moore Vance B. · CIK 0001550553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,415 F1 · shares: Grant of restricted shares in consideration of services as a Board Member. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:54 UTC |
Bauer Joanne BDirector
|
GrantCommon Stock | 243 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007935 · edgar.xml · nonDerivative · entry 3 Bauer Joanne B · CIK 0001359343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,525 F2 · shares: Grant of restricted shares in consideration for services as a member of the Corporate Governance Committee. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:54 UTC |
Bauer Joanne BDirector
|
GrantCommon Stock | 2,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007935 · edgar.xml · nonDerivative · entry 2 Bauer Joanne B · CIK 0001359343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,282 F1 · shares: Grant of restricted shares in consideration of services as a member of the Board of Directors. Shares vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:52 UTC |
Smith Bruce D.Director
|
GrantCommon Stock | 182 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007932 · edgar.xml · nonDerivative · entry 3 Smith Bruce D. · CIK 0001635537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,488 F2 · shares: Grant of restricted shares in consideration for services as a member of the Corporate Governance Committee. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:52 UTC |
Smith Bruce D.Director
|
GrantCommon Stock | 2,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007932 · edgar.xml · nonDerivative · entry 2 Smith Bruce D. · CIK 0001635537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,306 F1 · shares: Grant of restricted shares in consideration of service as a Board member. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:53 UTC |
PARRISH MARK WDirector
|
GrantCommon Stock | 182 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007934 · edgar.xml · nonDerivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,662 F2 · shares: Grant of restricted shares in consideration for services as a member of the Corporate Governance Committee. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:53 UTC |
PARRISH MARK WDirector
|
GrantCommon Stock | 2,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007934 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,480 F1 · shares: Grant of restricted shares in consideration of service as a Board member. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:53 UTC |
Judson James TDirector
|
GrantCommon Stock | 486 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007933 · edgar.xml · nonDerivative · entry 4 Judson James T · CIK 0001326789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,130 F3 · shares: Grant of restricted shares in consideration for services as the Chairman of the Audit Committee. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:53 UTC |
Judson James TDirector
|
GrantCommon Stock | 425 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007933 · edgar.xml · nonDerivative · entry 3 Judson James T · CIK 0001326789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,644 F2 · shares: Grant of restricted shares in consideration for services as the Lead Director. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:53 UTC |
Judson James TDirector
|
GrantCommon Stock | 2,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007933 · edgar.xml · nonDerivative · entry 2 Judson James T · CIK 0001326789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,219 F1 · shares: Grant of restricted shares in consideration of service as a Board member. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 19, 2017 Filed May 19, 2017 22:41 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $17.29 | $0.00 |
DisclosureSEC source: 0001179110-17-007643 · edgar.xml · derivative · entry 6 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 Underlying: Common Stock · 4,200 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: According to 10b5-1 dated March 8, 2017. Read SEC document |
| May 19, 2017 Filed May 19, 2017 22:41 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $16.70 | $0.00 |
DisclosureSEC source: 0001179110-17-007643 · edgar.xml · derivative · entry 5 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 Underlying: Common Stock · 4,200 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: According to 10b5-1 dated March 8, 2017. Read SEC document |
| May 19, 2017 Filed May 19, 2017 22:41 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
SaleCommon Stock | 8,000 | $40.65 | $325,206.40 |
DisclosureSEC source: 0001179110-17-007643 · edgar.xml · nonDerivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,696 F2 · price: The price reported in Column 4 is the Average price $40.6508. The selling price is between $40.30 to $40.90. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2017 Filed May 19, 2017 22:41 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
SaleCommon Stock | 8,400 | $40.69 | $341,781.72 |
DisclosureSEC source: 0001179110-17-007643 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,696 F1 · price: The price reported in Column 4 is the Average price $40.6883. The selling price is between $40.50 to $40.95. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2017 Filed May 19, 2017 22:41 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
Exercise / conversionCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007643 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: According to 10b5-1 dated March 8, 2017. Read SEC document |
| May 09, 2017 Filed May 9, 2017 21:40 UTC |
DREW J CHRISTOPHERExe VP, Sales & Marketing
|
SaleCommon Stock | 10,625 | $40.97 | $435,308.38 |
DisclosureSEC source: 0001179110-17-006943 · edgar.xml · nonDerivative · entry 3 DREW J CHRISTOPHER · CIK 0001271482 · Exe VP, Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,407 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F1 · price: The price reported in Column 4 is the average price and the shares sold between $40.925 to $41.15. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The transfer of balances between his accounts: We added 975 gifted shares to the directly owned balance and deducted the same shares from Family trust balance. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 15:23 UTC |
LIPPS RANDALL ADirector · Chairman, President, and CEO
|
Exercise / conversionNon-Qualified Options (right to buy) · Derivative | 18,200 | $0.00 Strike: $14.10 | $0.00 |
DisclosureSEC source: 0001179110-17-006203 · edgar.xml · derivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 15:23 UTC |
LIPPS RANDALL ADirector · Chairman, President, and CEO
|
SaleCommon Stock | 18,200 | $41.00 | $746,200.00 |
DisclosureSEC source: 0001179110-17-006203 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,982 F4 · price: The price reported in Column 4 is the Exact price for all the shares sold. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 15:23 UTC |
LIPPS RANDALL ADirector · Chairman, President, and CEO
|
Exercise / conversionCommon Stock | 18,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006203 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 22:28 UTC |
PETERSMEYER GARY SDirector
|
SaleCommon Stock | 2,658 | $37.45 | $99,542.10 |
DisclosureSEC source: 0001179110-17-004444 · edgar.xml · nonDerivative · entry 2 PETERSMEYER GARY S · CIK 0001206986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,427 F1 · shares: The price reported in Column 4 is the Exact price sold. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:14 UTC |
Taborga Jorge R.Executive VP. Engineering
|
Tax withholdingCommon Stock | 1,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004341 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,981 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:14 UTC |
Kuipers Peter J.Executive V.P. CFO
|
Tax withholdingCommon Stock | 761 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004340 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V.P. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,928 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:14 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
Tax withholdingCommon Stock | 1,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004339 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,696 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:14 UTC |
DREW J CHRISTOPHERExe VP, Sales & Marketing
|
Tax withholdingCommon Stock | 1,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004338 · edgar.xml · nonDerivative · entry 3 DREW J CHRISTOPHER · CIK 0001271482 · Exe VP, Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,586 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:13 UTC |
Seim Robin GeneEVP, Global A & M Adherence
|
Tax withholdingCommon Stock | 1,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004337 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · EVP, Global A & M Adherence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,814 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:13 UTC |
LIPPS RANDALL ADirector · Chairman, President, and CEO
|
Tax withholdingCommon Stock | 4,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004336 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,982 F3 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:13 UTC |
Ngo Nhat HExec. VP, Strategy & Bus Dev.
|
Tax withholdingCommon Stock | 1,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004335 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · Exec. VP, Strategy & Bus Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,392 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| February 21, 2017 Filed Feb 21, 2017 23:41 UTC |
WHITE SARA JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,443 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0001179110-17-002835 · edgar.xml · derivative · entry 4 WHITE SARA J · CIK 0001227559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,443 Underlying: Common Stock · 3,443 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2017 Filed Feb 21, 2017 23:41 UTC |
WHITE SARA JDirector
|
SaleCommon Stock | 3,443 | $38.06 | $131,023.37 |
DisclosureSEC source: 0001179110-17-002835 · edgar.xml · nonDerivative · entry 3 WHITE SARA J · CIK 0001227559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,214 F1 · price: The price reported in Column 4 is the Exact price sold. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2017 Filed Feb 21, 2017 23:41 UTC |
WHITE SARA JDirector
|
Exercise / conversionCommon Stock | 3,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002835 · edgar.xml · nonDerivative · entry 2 WHITE SARA J · CIK 0001227559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:26 UTC |
Ngo Nhat HExec. VP, Strategy & Bus Dev.
|
GrantStock Option (Right to Buy) · Derivative | 23,480 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002193 · edgar.xml · derivative · entry 4 Ngo Nhat H · CIK 0001305020 · Exec. VP, Strategy & Bus Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,480 Underlying: Common Stock · 23,480 shares Expires 2027-02-08 F1 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:26 UTC |
Ngo Nhat HExec. VP, Strategy & Bus Dev.
|
GrantCommon Stock | 9,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002193 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · Exec. VP, Strategy & Bus Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,308 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:26 UTC |
Ngo Nhat HExec. VP, Strategy & Bus Dev.
|
GrantCommon Stock | 2,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002193 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · Exec. VP, Strategy & Bus Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,768 F2 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
LIPPS RANDALL ADirector · Chairman, President, and CEO
|
GrantStock Option (Right to Buy) · Derivative | 134,160 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002192 · edgar.xml · derivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,160 Underlying: Common Stock · 134,160 shares Expires 2027-02-08 F4 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
LIPPS RANDALL ADirector · Chairman, President, and CEO
|
GrantCommon Stock | 54,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002192 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,705 F5 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
LIPPS RANDALL ADirector · Chairman, President, and CEO
|
GrantCommon Stock | 16,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002192 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,355 F3 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
DREW J CHRISTOPHERExe VP, Sales & Marketing
|
GrantStock Option (Right to Buy) · Derivative | 35,220 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002191 · edgar.xml · derivative · entry 5 DREW J CHRISTOPHER · CIK 0001271482 · Exe VP, Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,220 Underlying: Common Stock · 35,220 shares Expires 2027-02-08 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
DREW J CHRISTOPHERExe VP, Sales & Marketing
|
GrantCommon Stock | 14,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002191 · edgar.xml · nonDerivative · entry 4 DREW J CHRISTOPHER · CIK 0001271482 · Exe VP, Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,355 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
DREW J CHRISTOPHERExe VP, Sales & Marketing
|
GrantCommon Stock | 4,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002191 · edgar.xml · nonDerivative · entry 3 DREW J CHRISTOPHER · CIK 0001271482 · Exe VP, Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,525 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
Seim Robin GeneEVP, Global A & M Adherence
|
GrantStock Option (Right to Buy) · Derivative | 34,390 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002190 · edgar.xml · derivative · entry 4 Seim Robin Gene · CIK 0001351911 · EVP, Global A & M Adherence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,390 Underlying: Common Stock · 34,390 shares Expires 2027-02-08 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
Seim Robin GeneEVP, Global A & M Adherence
|
GrantCommon Stock | 13,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002190 · edgar.xml · nonDerivative · entry 3 Seim Robin Gene · CIK 0001351911 · EVP, Global A & M Adherence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,891 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:25 UTC |
Seim Robin GeneEVP, Global A & M Adherence
|
GrantCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002190 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · EVP, Global A & M Adherence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,931 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
GrantStock Option (Right to Buy) · Derivative | 23,480 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002189 · edgar.xml · derivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,480 Underlying: Common Stock · 23,480 shares Expires 2027-02-08 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
GrantCommon Stock | 9,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002189 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,047 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
GrantCommon Stock | 2,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002189 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,507 F1 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC |
Kuipers Peter J.Executive V.P. CFO
|
GrantStock Option (Right to Buy) · Derivative | 34,390 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002188 · edgar.xml · derivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V.P. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,390 Underlying: Common Stock · 34,390 shares Expires 2027-02-08 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC |
Kuipers Peter J.Executive V.P. CFO
|
GrantCommon Stock | 13,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002188 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V.P. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,689 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC |
Kuipers Peter J.Executive V.P. CFO
|
GrantCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002188 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V.P. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,729 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.